PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.01B | 827.11M | 1.73B | 1.78B | 1.76B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.01B | 827.11M | 1.73B | 1.78B | 1.76B |
| Cost of Revenue | 504.79M | 510.13M | 502.26M | 503.24M | 559.56M |
| Gross Profit | 503.97M | 316.98M | 1.23B | 1.28B | 1.21B |
| SG&A Expenses | 347.73M | 352.37M | 347.14M | 334.95M | 324.36M |
| Depreciation & Amortization | 40.31M | 32.53M | 24.74M | 18.70M | 14.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 892.83M | 895.02M | 874.15M | 856.89M | 898.12M |
| Operating Income | 115.93M | -67.91M | 856.51M | 922.26M | 866.81M |
| Income Before Tax | -67.07M | -235.67M | 696.62M | 741.00M | 666.09M |
| Income Tax Expenses | -28.69M | -48.94M | 13.98M | -10.72M | 36.91M |
| Earnings from Continuing Operations | -38.38 | -186.73 | 682.64 | 751.72 | 629.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.38M | -186.73M | 682.64M | 751.72M | 629.17M |
| EBIT | 115.93M | -67.91M | 856.51M | 922.26M | 866.81M |
| EBITDA | 171.23M | -20.90M | 895.32M | 954.94M | 894.86M |
| EPS Basic | -0.50 | -2.33 | 8.79 | 9.61 | 8.02 |
| Normalized Basic EPS | -0.68 | -2.01 | 5.47 | 6.99 | 6.43 |
| EPS Diluted | -0.59 | -2.34 | 7.73 | 8.55 | 6.97 |
| Normalized Diluted EPS | -0.73 | -1.98 | 4.78 | 6.30 | 5.72 |
| Average Basic Shares Outstanding | 324.69M | 319.83M | 315.43M | 311.94M | 310.39M |
| Average Diluted Shares Outstanding | 342.35M | 328.48M | 332.34M | 328.85M | 318.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |